Italy Leads Europe in Approving New Therapy for BRAF-Mutated Metastatic Colorectal Cancer
Italy has become the first country in Europe to provide national health service access to a new therapeutic combination for patients with metastatic colorectal cancer harboring a BRAF mutation, a particularly aggressive form of the disease. The combination therapy, consisting of encorafenib and cetuximab alongside traditional chemotherapy, has demonstrated the ability to double survival rates compared to standard treatments.
A Turning Point for Patients
Approximately 800 patients in Italy each year – representing 8-10% of those with metastatic disease – carry the BRAF mutation. Around 48,000 new cases of colorectal cancer are diagnosed in Italy annually. Previously considered a “last resort” treatment, this combination is now a first-line option, offering renewed hope to patients who historically faced limited therapeutic options and rapid disease progression.
Breakthrough Results from the BREAKWATER Study
The approval by the Italian Medicines Agency (AIFA) was expedited through a procedure designed for innovative medicines with urgent clinical need and strong scientific evidence, as outlined in law 648/96. This decision followed the results of the randomized phase three BREAKWATER study , which evaluated the combination of chemotherapy with encorafenib and cetuximab against the standard of care for patients with BRAF (V600E) mutated metastatic colorectal cancer.
Published in the New England Journal of Medicine, the study revealed that the new combination doubled overall survival, extending it from a median of 15-16 months to over 30 months. “This treatment represents a turning point for a patient population who, until a few years ago, had very limited therapeutic options and extremely rapid disease progression,” explains Fortunato Ciardiello, professor of medical oncology at the Luigi Vanvitelli University of Campania in Naples and one of the study’s authors.
The Importance of Early Mutation Testing
Identifying the BRAF mutation at the time of diagnosis is crucial for guiding treatment decisions. Molecular profiling of tumors allows oncologists to select the most effective drugs or combinations based on the cancer’s genetic makeup. However, access to these tests isn’t always guaranteed, as they are not always reimbursed by national health services and require sophisticated equipment.
“Identifying the BRAF mutation right from the diagnosis of metastatic disease allows us to immediately orient the therapeutic choice towards the most effective option,” emphasizes Stefania Napolitano, a medical oncology researcher at Vanvitelli University. “Colorectal cancer can no longer be considered a single disease: there are biologically different subtypes that require different therapeutic strategies, and recognizing them promptly means offering people the most appropriate therapy at the right time.”
Law 648/96 Facilitates Timely Access
The expedited approval process, facilitated by law 648/96, demonstrates the Italian National Health Service’s ability to make innovative therapies available quickly when supported by robust scientific evidence and a high clinical need. The Oncology Group of Southern Italy (GOIM) played a key role in accelerating access to this treatment.
“In this case it did so for one of the most aggressive forms of colorectal cancer, a type of cancer that today affects men and women to an almost identical extent and whose incidence is increasing in the under 50 population,” states Roberto Bordonaro, GOIM president and director of the Oncology Department at the Garibaldi Hospital in Catania. “The GOIM thus confirms its commitment to translating scientific evidence into concrete benefits for cancer patients, actively contributing to reducing therapeutic inequalities and improving standards of care.”